The end of BAC containing ophthalmic formulations?

27 July 2017 in News

Acute cytotoxic effects of the pharmaceutical excipients benzalkonium chloride (BAC), macrogolglycerol hydroxystearate (MGHS40), polysorbate 80 (PS80) and marketed ophthalmic formulations (Lumigan(R), Monoprost(R), Taflotan(R), Travatan(R), Xalatan(R)) containing these excipients were tested. Human corneal epithelial cell (HCE-T) viability was assessed by measuring the reduction of resazurin to highly fluorescent resorufin. The study was fully funded by Experimentica Ltd.